In-hospital and one-year outcomes in cancer patients receiving percutaneous coronary intervention for acute myocardial infarction: A real-world study
暂无分享,去创建一个
J. Day | Chaofeng Sun | Hui Liu | Guoliang Li | Yidan Wang | Xiangqi Cao | Manyun Tang
[1] G. Boriani,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal. Cardiovascular Imaging.
[2] G. Boriani,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal.
[3] G. Boriani,et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. , 2021, European heart journal. Acute cardiovascular care.
[4] A. Jemal,et al. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics , 2021, Journal of the National Cancer Institute.
[5] M. Kerneis,et al. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. , 2021, JAMA cardiology.
[6] H. Thiele,et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation. , 2020, European heart journal.
[7] F. Fernández-Vázquez,et al. Previously diagnosed cancer and mortality after ST‐segment elevation acute myocardial infarction treated with primary angioplasty , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[8] J. Ferrières,et al. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. , 2019, Archives of cardiovascular diseases.
[9] Yaiza Beatriz Molero-Díez,et al. Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.
[10] Arjun K. Ghosh,et al. Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges , 2019, Current Treatment Options in Oncology.
[11] C. Torp-Pedersen,et al. Incidence of new onset cancer in patients with a myocardial infarction – a nationwide cohort study , 2018, BMC Cardiovascular Disorders.
[12] Kristian Thygesen,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.
[13] J. Lima,et al. Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger , 2018, Circulation.
[14] Jeroen J. Bax,et al. Cardio-Oncology Services: rationale, organization, and implementation. , 2018, European heart journal.
[15] G. Hindricks,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.
[16] E. Yeh,et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. , 2017, Journal of the American College of Cardiology.
[17] C. Criscitiello,et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management , 2016, CA: a cancer journal for clinicians.
[18] A. Blaes,et al. Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.
[19] A. Franco,et al. Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.
[20] A. Abernethy,et al. Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention , 2015, Journal of the American Heart Association.
[21] J. Jukema,et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. , 2013, The American journal of cardiology.
[22] P. Marik,et al. Narrative Review , 2012, Journal of intensive care medicine.
[23] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[24] J. Tobis,et al. Causes of death in patients undergoing percutaneous coronary intervention with drug-eluting stents in a real-world setting. , 2009, The Journal of invasive cardiology.
[25] E. Yeh. Cardiotoxicity induced by chemotherapy and antibody therapy. , 2006, Annual review of medicine.
[26] Doris J Folger. Together we are stronger. , 2005, Minnesota medicine.
[27] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[28] B. Lewis,et al. [The new universal definition of myocardial infarction]. , 2009, Harefuah.